News | June 07, 2021
Bayer acquires Noria and PSMA Therapeutics
Broadens company’s oncology platform of Targeted Alpha Therapies (TATs)
Broadens company’s oncology platform of Targeted Alpha Therapies (TATs)
The company has registered total income of Rs. 3,847 crores for Q4 FY21, up by 3% on a y-o-y basis from Rs. 3,752 crores registered during corresponding period of the previous year
Nanoform and Celanese intend to work on formulation development, leveraging each organization's unique formulation expertise.
New agreement for three further production lines at Lonza’s site in Visp, Switzerland
New manufacturing complex will occupy an overall footprint of approximately 2,000 square meter with six levels of manufacturing space
Strategic divestment of Ploermel and Edinburgh sites will enable NextPharma to benefit from operational synergies and optimize existing expertise and technologies
The DREAM-ND Phase III trial has now enrolled 588 CKD patients not-on-dialysis.
EBITDA and PAT for the quarter were both up 11% to Rs. 193 crores and Rs. 102 crores respectively.
Subscribe To Our Newsletter & Stay Updated
